🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT07681180
Starting soon Not applicable

Evaluation of Anxiety Reduction in the Cathlab by Means of Pharmacological and Non-pharmacological Strategies

NCT07681180 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2026-08
Last updated
2026-07-02

Condition(s) studied

Cardiovascular DiseaseCardiovascular CarePain and Anxiety During Cardiac Catheterization

Investigational drug(s) / intervention(s)

Auditive experienceAudiovisual immersive experience

Auditive experience: Auditive distraction therapy

Audiovisual immersive experience: Virtual reality-lead audiovisual experience

Study summary

The goal of this prospective pilot study is to learn if the use of virtual reality and/or relaxing soundscapes can help lower anxiety in adult patients undergoing a scheduled coronary angiography or angioplasty as compared to the standard of care. The main questions it aims to answer are:

* The use of non-pharmacological strategies reduces intraprocedural stress and anxiety compared to standard of care
* Reducing anxiety limits the use of pharmacological agents, which increases patient safety.

Researchers will compare the use of relaxing soundscapes or virtual reality to the standard of care to see the effects of these strategies on pain, anxiety and stress.

Participants will:

* listen to relaxing soundscapes, OR experience virtual reality including soundscapes OR standard of care during their procedure,
* Answer pain, anxiety and recovery questionnaires,
* Answer satisfaction questionnaires.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults, 18 years or older * Scheduled hemodynamic intervention (coronary angiography and/or angioplasty) * Patient willing and able to understand the study * Signed informed consent Exclusion Criteria: * Scheduled complex procedure (CTO, structural) * Severe cognitive or psychiatric disorders * Major hearing/visual impairment * Severe motion sickness or history of malaise with Virtual Reality (VR) * Complaints of nausea or vomiting * History of epilepsy * Claustrophobia * Facial injuries * In clinical isolation (infection control)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
IUCPQ Québec Quebec

More Olivier F. Bertrand trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07681180 on ClinicalTrials.gov ↗ ← All trials in Canada